Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 27, 2018updated 03 Dec 2021 10:34am

Glaukos’ iStent inject micro-bypass device gets FDA approval

Ophthalmic medical technology company Glaukos has obtained the US Food and Drug Administration (FDA) premarket approval (PMA) for its iStent inject Trabecular Micro-Bypass System.

Ophthalmic medical technology company Glaukos has obtained the US Food and Drug Administration (FDA) premarket approval (PMA) for its iStent inject Trabecular Micro-Bypass System.

The approval covers the use of the system to decrease intraocular pressure (IOP) in adults with mild-to-moderate primary open-angle glaucoma (POAG) and undergoing concomitant cataract surgery.

iStent inject creates two bypasses in the trabecular meshwork to enable multi-directional flow through Schlemm’s canal for optimising the natural aqueous humor outflow.

“Glaukos is planning to begin preparations for the initial commercial launch of the micro-bypass system in the third quarter of this year.”

The next-generation trabecular micro-bypass device features two heparin-coated titanium stents that are preloaded into an auto-injection system.

This capability is said to facilitate precise implantation of stents into two trabecular meshwork locations via only one corneal entry point with a click-and-release motion.

Glaukos president and CEO Thomas Burn said: “The approval of iStent inject represents another major Glaukos milestone in the pursuit of our mission to transform glaucoma therapy and further strengthens our position at the forefront of micro-scale innovation.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

“Given its clinical performance and enhanced procedural elegance, we believe the iStent inject will be an attractive, two-stent solution for US ophthalmic surgeons to reliably manage glaucoma patients’ IOP in a straightforward and effective manner.”

The FDA decision comes after a review of results from a randomised, multi-centre clinical trial conducted in 505 patients with mild to moderate POAG at 41 clinical sites.

Findings indicated a statistically significant decrease in unmedicated diurnal IOP in subjects undergoing cataract surgery, with the iStent inject at 24 months.

Glaukos is planning to begin preparations for the initial commercial launch of the micro-bypass system in the third quarter of this year.

Currently, the device is commercially available in the European Union, Australia, Canada, Brazil, Armenia, Singapore, Hong Kong and South Africa.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU